SAN FRANCISCO, March 2, 2021 /PRNewswire/ -- The global antibiotics market size is expected to reach USD 57.99 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 4.5% from 2021 to 2028. High usage of antibiotics and inappropriate prescription behavior of antibiotic drugs worldwide are the major factors anticipated to drive the market. Moreover, rising awareness among patients and healthcare professionals and increasing involvement of regulatory bodies in the R&D activities of new therapies to treat infectious diseases are expected to propel the market growth over the forecast period.
Key suggestions from the report:
- By action mechanism, the cell wall synthesis inhibitors segment accounted for the largest share of 52.1% in 2020 and is anticipated to maintain its lead over the forecast period
- Based on drug class, the cephalosporin segment held the second-largest share in 2020. Pipeline candidates in cephalosporin drug class such as Fetroja (cefiderocol), cefilavancin, and ceftobiprole are anticipated to drive the segment in the forecast period
- The others' drug class segment is expected to grow at the fastest rate during the forecast period. The segment consists of various existing classes of antibiotics as well as some newly developed drugs, such as tetracycline, carbapenem, imidazole, peptides, lincosamides, and monoclonal antibodies
- Asia Pacific was the largest regional market in 2020 and is expected to witness the fastest growth in the coming years owing to the rising consumption of antibiotics and high disease prevalence
- North America emerged as the second-largest regional market in 2020 owing to government initiatives for the development of new therapies and better reimbursement scenario
Read 120 page research report with ToC on "Antibiotics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, Sulfonamide, 7-ACA), By Action Mechanism, And Segment Forecasts, 2021 - 2028" at:https://www.grandviewresearch.com/industry-analysis/antibiotic-market
An increasing number of public-private collaborations, wherein funding and innovative R&D approaches are provided by public agencies to firms developing antibiotics, is expected to boost the product pipeline. For instance, in December 2018, Eisai Co., Ltd., and Takeda Pharmaceutical Company Limited announced an agreement with GARDP for the development of novel antibacterial compounds.
Betterment in the approval process of antibiotic drugs is expected to boost the market growth over the forecast period. In February 2020, Merck received acceptance for a review of supplemental New Drug Application (sNDA) from the U.S. FDA for RECARBRIO (imipenem, cilastatin, and relebactam) intended for HABP/VABP. This submission is anticipated to reinforce the continued dedication of the company to R&D pertaining to antibiotic therapies that address unmet medical needs.
Government reforms such as the Generating Antibiotics Incentives Now Act in the U.S. are projected to propel market growth in the coming years. This is further expected to facilitate the development process of advanced drugs. According to the Pew Charitable Trusts, about 30% of the outpatient oral antibiotic drug prescriptions are unnecessary and most of these prescriptions are for disease conditions against which antibiotics are not significantly effective, such as non-bacterial infections and acute respiratory conditions.
The market is highly competitive and major market players have almost similar market share. Pharmaceutical players are adopting strategies, including mergers & acquisitions, collaborations, and strategic alliances, to gain a competitive advantage. The major pharmaceutical companies are collaborating for developing novel therapies to reduce the cost burden of the drug development process. In December 2019, Appili Therapeutics signed an agreement with Saptalis Pharmaceuticals for the reformulation of antibiotic metronidazole. According to the agreement, Saptalis will be responsible for manufacturing, marketing of ATI-1501 in the United States. Moreover, in October 2018, Paratek Pharmaceuticals, Inc. entered into a license agreement for the development and commercialization of Seysara (sarecyline) with Allergan.
A group of key pharmaceutical players has launched AMR Action Fund worth USD 1 billion in July 2020. This fund is expected to support the research of innovative and novel antibiotics and is formed in collaboration with the European Investment Bank, the Wellcome Trust, and the World Health Organization.
Due to the lack of commercial success for newly developed antimicrobial drugs, government and non-government bodies have adopted strategies to incentivize antibiotic drug R&D activities. For instance, the government in alliance with BARDA is supporting several companies to boost the R&D activities in new therapies for infectious diseases. BARDA has also been associated with pharmaceutical companies, such as GSK, Tetraphase, and Basilea Astra Zeneca. CARB-X is investing around USD 109 million to support the early-stage development of potential therapeutic candidates.
Grand View Research has segmented the global antibiotics market on the basis of action mechanism, drug class, and region:
- Antibiotics Action Mechanism Outlook (Revenue, USD Million, 2017 - 2028)
- Cell Wall Synthesis Inhibitors
- Protein Synthesis Inhibitors
- DNA Synthesis Inhibitors
- RNA Synthesis Inhibitors
- Mycolic Acid Inhibitors
- Others
- Antibiotics Drug Class Outlook (Revenue, USD Million, 2017 - 2028)
- Cephalosporin
- Penicillin
- Fluoroquinolone
- Macrolide
- Carbapenem
- Aminoglycoside
- Sulfonamide
- 7-ACA
- Others
- Antibiotics Regional Outlook (Revenue, USD Million, 2017 - 2028)
- North America
- U.S
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- India
- China
- Japan
- Thailand
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
List of Key Players of Antibiotics Market
- Merck & Co., Inc.
- Allergan plc (AbbVie)
- GlaxoSmithKline plc.
- Pfizer Inc.
- Melinta Therapeutics
- Basilea Pharmaceutica Ltd.
- Tetraphase Pharmaceuticals
- Paratek Pharmaceuticals, Inc.
- Nabriva Therapeutics plc
- Spero Therapeutics
Find more research reports onPharmaceuticals Industry, by Grand View Research:
- Monoclonal Antibodies Market - The global monoclonal antibodies market accounted for USD 85.4 billion in 2015 and is expected to exhibit a growth rate of 5.7% over the forecast period.
- Animal Feed Additives Market - The global animal feed additives market size was USD 37.83 billion in 2019 and is projected to expand at a CAGR of 3.8% from 2020 to 2027.
- Crohn's Disease Therapeutics Market - The global Crohn's disease therapeutics market size was estimated at USD 3.8 billion in 2016 and is expected to register a CAGR of 2.4% during the forecast period.
Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter
Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg
